Novartis takes the long view on CAR-T, grabbing licenses on new tech for next-gen therapies
After lining up their application for a pioneering CAR-T therapy, Novartis’ $NVS cell therapy group is demonstrating some longterm interest in the field, bagging licensing deals on new tech to help deliver their therapy as well as focus on next-gen off-the-shelf cell therapies that are forming in a second wave of experimental programs.
Early this morning the Belgian biotech Celyad $CYAD announced that Novartis had gained non-exclusive rights to IP it has on allogeneic CAR-Ts, off-the-shelf cell therapies for cancer that many believe could eventually prove superior to the autologous programs now lining up for an approval from Kite and Novartis. The lead autologous drugs extract T cells from patients and then engineer them into therapies targeting cancer cells. Allogeneic CAR-Ts will use generic T cells, but have to be able to avoid being rejected by the host — a major challenge.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.